Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mepolizumab IV vs SC PK/PD in Asthma
NCT01366521Phase 2Completed
- Sponsor
- GSK
- Start
- Feb 2011
- Primary completion
- Mar 2012
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 2, randomised, open-label trial of mepolizumab in asthma (4 arms), sponsored by GSK. Primary endpoints: Change From Baseline in Blood Eosinophil Levels at Week 12, Area Under the Blood Eosinophil Time Curve at Day 84 and 5 more. Started Feb 2011; status: completed.
02
Drugs
mepolizumab
03
Conditions
asthma
Beyond the preview
Go deeper on NCT01366521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01366521.